跳至主要内容
临床试验/CTRI/2020/05/025216
CTRI/2020/05/025216已完成不适用

Evaluation of Cardiac Safety of Hydroxychloroquin for pre COVID 19 Exposure Prophylaxis : Smart Remote Continuous Ambulatory Electrocardiographic Study

Rohit Walia1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2020年5月26日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
Rohit Walia
入组人数
30
试验地点
1
主要终点
No of patients with QT prolongation by 25 percentage of baseline

研究概览

简要总结

Normal people taking hydroxchloroquin for COVID 19 pre exposure prophylaxis will be monitored through contnous ambulatory telemetry device for any QT prolongation and arrhythmias for continuous seven days from start of medicine to generate cardiac safety data.

研究设计

研究类型
Observational

入排标准

年龄范围
20.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • people taking pre exposure COVID 19 hydroxychloroquin prophylaxis Written informed consent.

排除标准

  • Corrected QT greater than 480 ms Known congenital Long QT Co moralities and contraindications to hydroxychloroquin Retinopathy Known hypersensitivity to chloroquine Cardiomyopathy, prolonged QTc, cardiac arrhythmias • History of psoriasis, porphyria cutanea tarda Epilepsy Myasthenia gravis, myopathy of any cause Serious hepatic or renal disease Known glucose-6-phosphate dehydrogenase deficiency Current use of medication with known serious hepatotoxic effects or known interaction with chloroquine Severe depression Electrolyte imbalance Anti arrhythmic drugs Cardiac devices like pacemaker , defibrillators.

结局指标

主要结局

No of patients with QT prolongation by 25 percentage of baseline

时间窗: 7 days

No of patients with QT prolongation greater than 500 ms

时间窗: 7 days

No of patients with ventricular arrhythmias

时间窗: 7 days

Syncope

时间窗: 7 days

Sudden cardiac Death

时间窗: 7 days

次要结局

  • Any drug related adverse events(Any Syncope , all cause mortality)

研究者

发起方
Rohit Walia
申办方类型
Other [ Principal investigator ]

研究点 (1)

Loading locations...

相似试验